Biohaven Explores New Horizons Despite Recent Setbacks Despite challenges, Biohaven is advancing its pipeline, including taldefgrobep alfa for obesity and BHV-1300 for autoimmune conditions. While recent trials have faced hurdles, the company remains committed to innovation in neuroscience and immunology, aiming to capture market opportunities in high-unmet-need areas.45